Abstract
Non-small-cell lung cancer is the leading cause of cancer death in the US despite advances in therapy. The epidermal-growth-factor receptor has been investigated as a target for therapy using EGFR-specific tyrosine kinase inhibitors. This Viewpoint discusses the implications of the correlation of positive responses seen in patients harboring EGFR mutations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
